According to a new 13G filing with the Securities and Exchange Commission, Bihua Chen‘s Cormorant Asset Management owns 900,000 shares of Gemphire Therapeutics Inc. (NASDAQ:GEMP), which amass 9.7% of the company’s outstanding stock. Gemphire Therapeutics represents a new addition to Cormorant Asset Management’s portfolio.
Gemphire Therapeutics is a clinical-stage biopharmaceutical company engaged in discovering and producing therapeutics to help treat people suffering from dyslipidemia. The company started trading on August 8 and since then its stock has gained 8.7%.
There are no other funds in our database with a known long position in Gemphire Therapeutics Inc. (NASDAQ:GEMP) at this time.
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Cormorant Global Healthcare Master Fund | 0 | 748,350 | 0 | 748,350 | 748,350 | 8.1% |
Cormorant Global Healthcare GP | 0 | 748,350 | 0 | 748,350 | 748,350 | 8.1% |
Cormorant Asset Management | 0 | 900,000 | 0 | 900,000 | 900,000 | 9.7% |
Bihua Chen | 0 | 900,000 | 0 | 900,000 | 900,000 | 9.7% |
Follow Bihua Chen's Cormorant Asset Management
Page 1 of 8 – SEC Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | ||
SCHEDULE 13G | ||
Under the Securities Exchange Act of 1934 | ||
(Amendment No. ___)* |
Gemphire Therapeutics Inc. | ||
(Name of Issuer) |
Common Stock, par value $0.001 per share | ||
(Title of Class of Securities) |
36870A108 | ||
(CUSIP Number) |
August 5, 2016 | ||
(Date of Event which Requires Filing of this Statement) |
Page 2 of 8 – SEC Filing
1 | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Global Healthcare Master Fund, LP | |
2 | Check the Appropriate Box if a Member of a Group (See Instructions) | |
(a) [ ] | ||
(b) [x] | ||
3 | SEC Use Only | |
4 | Citizenship or Place of Organization. Cayman Islands | |
Number of Shares Beneficially Owned by Each Reporting Person With | 5 Sole Voting Power 0 shares | |
6 Shared Voting Power 748,350 shares Refer to Item 4 below. | ||
7 Sole Dispositive Power 0 shares | ||
8 Shared Dispositive Power 748,350 shares Refer to Item 4 below. | ||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person 748,350 shares Refer to Item 4 below. | |
10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A | |
11 | Percent of Class Represented by Amount in Row (9)* 8.1% Refer to Item 4 below. | |
12 | Type of Reporting Person (See Instructions) PN (Partnership) |
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Page 3 of 8 – SEC Filing
1 | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Global Healthcare GP, LLC | |
2 | Check the Appropriate Box if a Member of a Group (See Instructions) | |
(a) [ ] | ||
(b) [x] | ||
3 | SEC Use Only | |
4 | Citizenship or Place of Organization. Delaware | |
Number of Shares Beneficially Owned by Each Reporting Person With | 5 Sole Voting Power 0 shares | |
6 Shared Voting Power 748,350 shares Refer to Item 4 below. | ||
7 Sole Dispositive Power 0 shares | ||
8 Shared Dispositive Power 748,350 shares Refer to Item 4 below. | ||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person 748,350 shares Refer to Item 4 below. | |
10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A | |
11 | Percent of Class Represented by Amount in Row (9)* 8.1% Refer to Item 4 below. | |
12 | Type of Reporting Person (See Instructions) OO (Limited Liability Company) |
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Page 4 of 8 – SEC Filing
1 | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Cormorant Asset Management, LLC | |
2 | Check the Appropriate Box if a Member of a Group (See Instructions) | |
(a) [ ] | ||
(b) [x] | ||
3 | SEC Use Only | |
4 | Citizenship or Place of Organization. Delaware | |
Number of Shares Beneficially Owned by Each Reporting Person With | 5 Sole Voting Power 0 shares | |
6 Shared Voting Power 900,000 shares Refer to Item 4 below. | ||
7 Sole Dispositive Power 0 shares | ||
8 Shared Dispositive Power 900,000 shares Refer to Item 4 below. | ||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person 900,000 shares Refer to Item 4 below. | |
10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A | |
11 | Percent of Class Represented by Amount in Row (9)* 9.7% Refer to Item 4 below. | |
12 | Type of Reporting Person (See Instructions) OO (Limited Liability Company) |
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Page 5 of 8 – SEC Filing
1 | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Bihua Chen | |
2 | Check the Appropriate Box if a Member of a Group (See Instructions) | |
(a) [ ] | ||
(b) [x] | ||
3 | SEC Use Only | |
4 | Citizenship or Place of Organization. United States | |
Number of Shares Beneficially Owned by Each Reporting Person With | 5 Sole Voting Power 0 shares | |
6 Shared Voting Power 900,000 shares Refer to Item 4 below. | ||
7 Sole Dispositive Power 0 shares | ||
8 Shared Dispositive Power 900,000 shares Refer to Item 4 below. | ||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person 900,000 shares Refer to Item 4 below. | |
10 | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] N/A | |
11 | Percent of Class Represented by Amount in Row (9)* 9.7% Refer to Item 4 below. | |
12 | Type of Reporting Person (See Instructions) IN (Individual) |
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Page 6 of 8 – SEC Filing
(a) | Name of Issuer |
Gemphire Therapeutics Inc. | |
(b) | Address of Issuer’s Principal Executive Offices |
43334 Seven Mile Road, Suite 1000 Northville, MI 48167 |
(a) | Name of Person Filing |
Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Asset Management, LLC Bihua Chen | |
(b) | Address of Principal Business Office or, if none, Residence |
200 Clarendon Street, 52nd Floor Boston, MA 02116 | |
(c) | Citizenship |
Cormorant Global Healthcare Master Fund, LP – Cayman Islands Cormorant Global Healthcare GP, LLC – Delaware Cormorant Asset Management, LLC – Delaware Bihua Chen – United States | |
(d) | Title of Class of Securities |
Common Stock | |
(e) | CUSIP Number 36870A108 |
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Follow Neurobo Pharmaceuticals Inc. (NASDAQ:NRBO)
Page 7 of 8 – SEC Filing
Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
(a) | [ ] | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). |
(b) | [ ] | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). |
(c) | [ ] | Insurance Company as defined in Section 3(a)(19) of the Act |
(d) | [ ] | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). |
(e) | [ ] | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
(f) | [ ] | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
(g) | [ ] | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
(h) | [ ] | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
(i) | [ ] | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
(j) | [ ] | A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J); |
(k) | [ ] | Group, in accordance with §240.13d-1(b)(1)(ii)(K). |
Item 4. | Ownership*** |
(a) | Amount Beneficially Owned*** | |
Cormorant Global Healthcare Master Fund, LP – 748,350 shares Cormorant Global Healthcare GP, LLC – 748,350 shares Cormorant Asset Management, LLC – 900,000 shares Bihua Chen – 900,000 shares | ||
(b) | Percent of Class | |
Cormorant Global Healthcare Master Fund, LP – 8.1% Cormorant Global Healthcare GP, LLC – 8.1% Cormorant Asset Management, LLC – 9.7% Bihua Chen – 9.7% | ||
(c) | Number of shares as to which such person has: | |
(i) | sole power to vote or to direct the vote | |
Cormorant Global Healthcare Master Fund, LP – 0 shares Cormorant Global Healthcare GP, LLC – 0 shares Cormorant Asset Management, LLC – 0 shares Bihua Chen – 0 shares | ||
(ii) | shared power to vote or to direct the vote | |
Cormorant Global Healthcare Master Fund, LP – 748,350 shares Cormorant Global Healthcare GP, LLC – 748,350 shares Cormorant Asset Management, LLC – 900,000 shares Bihua Chen – 900,000 shares | ||
(iii) | sole power to dispose or to direct the disposition of | |
Cormorant Global Healthcare Master Fund, LP – 0 shares Cormorant Global Healthcare GP, LLC – 0 shares Cormorant Asset Management, LLC – 0 shares Bihua Chen – 0 shares | ||
(iv) | shared power to dispose or to direct the disposition of | |
Cormorant Global Healthcare Master Fund, LP – 748,350 shares Cormorant Global Healthcare GP, LLC – 748,350 shares Cormorant Asset Management, LLC – 900,000 shares Bihua Chen – 900,000 shares |
Item 5. | Ownership of Five Percent or Less of a Class |
Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company |
Item 8. | Identification and Classification of Members of the Group |
Item 9. | Notice of Dissolution of Group |
Item 10. | Certification |